MARKET

LIMN

LIMN

Liminatus Pharma
NASDAQ
0.1875
-0.0076
-3.90%
After Hours: 0.1900 +0.0025 +1.33% 19:59 03/27 EDT
OPEN
0.1920
PREV CLOSE
0.1951
HIGH
0.1959
LOW
0.1825
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
33.66
52 WEEK LOW
0.1825
MARKET CAP
7.38M
P/E (TTM)
-2.1527
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LIMN last week (0316-0320)?
Weekly Report · 5d ago
Liminatus Pharma to initiate Phase 1 clinical trial for IBA101 antibody
TipRanks · 03/17 12:16
Liminatus Intends To Start Phase 1 Clinical Study Of CD47-Blocking Monoclonal Antibody
Benzinga · 03/17 12:14
Liminatus Pharma plans Phase 1 trial of CD47 antibody IBA101 in lung cancer
Reuters · 03/17 12:08
LIMINATUS PHARMA ANNOUNCES PLANNED PHASE 1 CLINICAL TRIAL OF IBA101, A NEXT-GENERATION CD47 BLOCKING ANTIBODY
Reuters · 03/17 12:08
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
Barchart · 03/17 07:08
Weekly Report: what happened at LIMN last week (0309-0313)?
Weekly Report · 03/16 10:25
Weekly Report: what happened at LIMN last week (0302-0306)?
Weekly Report · 03/09 10:26
More
About LIMN
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.

Webull offers Liminatus Pharma Inc stock information, including NASDAQ: LIMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIMN stock methods without spending real money on the virtual paper trading platform.